ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Administered By

Duke Cancer Institute

Awarded By

Clovis Oncology, Inc.

Contributors

Harrison, Michael Roger Principal Investigator

Start/End

December 11, 2018 - September 30, 2020